{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:42:05Z","timestamp":1772160125439,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>In people with type 2 diabetes (T2D) requiring intensification beyond glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs) and oral antihyperglycaemic drugs (OADs), switching to iGlarLixi was shown to be efficacious and well\u2010tolerated in the LixiLan\u2010G trial. This exploratory analysis of LixiLan\u2010G assessed the efficacy and safety of switching to iGlarLixi versus continuing GLP\u20101 RA therapy, stratified by screening HbA1c level (\u22657.0 to \u22647.5 %; &gt;7.5 to \u22648.0 %; &gt;8.0 to \u22649.0 % [\u226553 to \u226458 mmol\/mol; &gt;58 to \u226464 mmol\/mol; &gt;64 to \u226475 mmol\/mol]) and previous GLP\u20101 RA regimen at screening (once\/twice daily or once weekly).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Endpoints for all subgroups included: change in HbA1c, achievement of HbA1c &lt;7 % and hypoglycaemia events. Adverse events and changes in fasting plasma glucose (FPG), 2\u2010hour postprandial plasma glucose (PPG), 2\u2010hour PPG excursion and weight were analysed according to previous GLP\u20101 RA regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Switching to iGlarLixi in all subgroups resulted in significantly greater reductions in HbA1c and proportions of participants reaching HbA1c &lt;7\u2009% (including with no documented hypoglycaemia) at Week 26 compared with continued GLP\u20101 RA treatment. Switching to iGlarLixi also led to significantly greater reductions in FPG, 2\u2010hour PPG, and 2\u2010hour PPG excursion, irrespective of previous GLP\u20101 RA regimen. Rates of hypoglycaemia were low, but slightly higher in those who switched to iGlarLixi for all subgroups. Modest weight gain was seen with iGlarLixi, irrespective of previous GLP\u20101 RA regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to iGlarLixi improved glycaemic control, regardless of screening HbA1c or previous GLP\u20101 RA type, offering a simple, efficacious and well\u2010tolerated treatment intensification option for people with T2D inadequately controlled by GLP\u20101 RAs and OADs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14345","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T04:47:13Z","timestamp":1612932433000},"page":"1331-1341","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Switching to\n                    <scp>iGlarLixi<\/scp>\n                    versus continuation of a daily or weekly glucagon\u2010like peptide\u20101 receptor agonist (\n                    <scp>GLP<\/scp>\n                    \u20101\n                    <scp>RA<\/scp>\n                    ) in insufficiently controlled type 2 diabetes: A\n                    <scp>LixiLan\u2010G<\/scp>\n                    trial subgroup analysis by HbA1c and\n                    <scp>GLP<\/scp>\n                    \u20101\n                    <scp>RA<\/scp>\n                    use at screening"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City  Dallas Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0492-6698","authenticated-orcid":false,"given":"Lawrence","family":"Blonde","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Ochsner Medical Center Frank Riddick Diabetes Institute  New Orleans Louisiana USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-4585","authenticated-orcid":false,"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-1255","authenticated-orcid":false,"given":"Juan","family":"Frias","sequence":"additional","affiliation":[{"name":"National Research Institute  Los Angeles California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Souhami","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Ji","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5388-0270","authenticated-orcid":false,"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[{"name":"School of Medicine University of Pisa  Pisa Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106821"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0218-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0610"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7425925"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-018-1018-0"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14202"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13444"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14345","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:28:56Z","timestamp":1761874136000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/dom.14345"],"URL":"https:\/\/doi.org\/10.1111\/dom.14345","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14345\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14345\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"2020-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}